Nova Eye Medical (EYE) AI Stock Analysis

• Market Cap: AU$35.52M
• Dividend Yield: N/A
• Average Volume (3M): 382.21K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.63
• Revenue Growth: 39.08%
• EPS Growth: 53.31%
• Country: AU
• Employees: 301
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Devices
• EPS (TTM): -0.04
• Shares Outstanding: 284,146,000
• 10 Day Avg. Volume: 536,452
• 30 Day Avg. Volume: 382,215
• PEG Ratio: -0.03
• Price to Book (P/B): 1.78
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.50
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 53 Neutral
• Price Target: AU$0.00 ▼(-100.00%Downside)

The stock score is primarily influenced by financial performance and technical analysis. Revenue growth is a positive factor, but profitability and cash flow challenges weigh heavily. Technical indicators suggest a neutral trend. Valuation concerns due to a negative P/E ratio further impact the score.

Nova Eye Medical Business Overview & Revenue Model

Company Description

Nova Eye Medical Limited designs, develops, distributes, markets, sells, and services surgical devices for the treatment of glaucoma. The company offers iTrack, a surgical system for the reduction in intraocular pressure (IOP) in adult patients with open-angle glaucoma; iTrack Advance, a natural ocular drainage system; Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma; and 2RT, a proprietary laser technology to treat patients in early/intermediate age-related macular degeneration. It operates in Australia, the United States, Europe, the Asia Pacific, and internationally. The company was formerly known as Ellex Medical Lasers Limited and changed its name to Nova Eye Medical Limited in July 2020. Nova Eye Medical Limited was founded in 1985 and is headquartered in Kent Town, Australia.

How the Company Makes Money

Nova Eye Medical generates revenue through the sale of its proprietary ophthalmic devices and treatment solutions to healthcare providers and ophthalmologists. The company's key revenue streams include the commercialization of its iTrack and Molteno3 devices, which are used in minimally invasive glaucoma surgeries (MIGS). Additionally, Nova Eye Medical may engage in strategic partnerships and collaborations with other medical technology firms to enhance its product offerings and distribution networks, further contributing to its earnings. Revenue is also driven by ongoing product development and innovation, ensuring the company remains competitive in the ophthalmic medical device market.

Nova Eye Medical Financial Statement Overview

Summary

Nova Eye Medical is experiencing strong revenue growth, but struggles with profitability and cash flow management. The balance sheet is stable with low leverage, yet improvements in operational efficiency and cash generation are needed for long-term sustainability.

Income Statement

Nova Eye Medical has shown a strong revenue growth of 37.06% from 2023 to 2024, indicating a positive growth trajectory. However, the company continues to struggle with profitability, evidenced by negative EBIT and Net Income margins, which suggests ongoing challenges in cost management and operational efficiency.

Balance Sheet

The balance sheet of Nova Eye Medical is relatively stable with a moderate debt-to-equity ratio of 0.16 in 2024, indicating low leverage. However, the declining equity ratio from 2023 to 2024 suggests potential risks in maintaining asset efficiency and shareholder value over time.

Cash Flow

Nova Eye Medical's cash flow statements reveal negative free cash flow, reflecting challenges in generating cash from operations. The operating cash flow to net income ratio is negative, indicating cash flow issues. Despite these challenges, financing activities have provided some liquidity support.

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	26.11M	23.32M	17.02M	13.38M	13.39M	12.77M
Gross Profit	19.82M	20.19M	842.00K	-765.00K	1.77M	-1.64M
EBITDA	-6.72M	-5.98M	-9.48M	-7.89M	-3.67M	-5.75M
Net Income	-8.56M	-8.79M	-15.29M	-7.50M	-4.36M	-6.99M
Balance Sheet
Total Assets	25.66M	29.88M	30.36M	36.63M	41.99M	116.74M
Cash, Cash Equivalents and Short-Term Investments	2.26M	6.15M	7.42M	8.00M	17.80M	95.65M
Total Debt	3.38M	3.35M	1.53M	1.94M	3.70M	3.34M
Total Liabilities	8.29M	8.55M	7.17M	6.23M	6.66M	16.16M
Stockholders Equity	17.38M	21.33M	23.19M	30.40M	35.34M	100.59M
Cash Flow
Free Cash Flow	-7.42M	-8.31M	-7.52M	-10.27M	-15.13M	3.79M
Operating Cash Flow	-7.32M	-7.86M	-6.72M	-4.68M	-12.90M	5.45M
Investing Cash Flow	-230.00K	-325.00K	-800.00K	-4.58M	-3.22M	88.26M
Financing Cash Flow	6.89M	6.91M	6.82M	-402.00K	-61.61M	-13.29M

Nova Eye Medical Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.12
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EYE, the sentiment is Positive. The current price of 0.12 is above the 20-day moving average (MA) of 0.12, above the 50-day MA of 0.12, and below the 200-day MA of 0.14, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 58.06 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:EYE.

Nova Eye Medical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	60 Neutral	HK$15.71B	5.67	-7.43%	4.09%	11.60%	-21.06%
EYE	53 Neutral	AU$35.52M	―	-50.50%	―	39.08%	53.31%
CYC	49 Neutral	AU$123.92M	―	-35.20%	―	4.68%	-155.42%
CMP	48 Neutral	AU$49.98M	―	-8.08%	―	-5.62%	-225.71%
EMV	46 Neutral	AU$149.65M	―	-58.61%	―	―	-74.88%
MX1	44 Neutral	AU$30.02M	―	-135.33%	―	-27.58%	33.69%
CBL	39 Underperform	AU$9.43M	―	-98.08%	―	-7.44%	30.34%

Nova Eye Medical Corporate Events

Nova Eye Medical to Host Investor Webinar on FY25 Sales Results

Nova Eye Medical Limited has announced an upcoming Investor Webinar scheduled for July 9, 2025, where Managing Director Tom Spurling will discuss the company’s sales results for the fiscal year 2025. This event provides an opportunity for stakeholders to engage with the company, potentially impacting investor relations and market perception of Nova Eye Medical’s performance and strategic direction.

Nova Eye Medical Announces Cessation of Performance Rights

Nova Eye Medical Limited has announced the cessation of 7,000 performance rights, as the conditions for these securities have not been met or have become incapable of being satisfied. This development may impact the company’s capital structure and could have implications for its stakeholders, reflecting a potential shift in the company’s operational or strategic focus.

Nova Eye Medical Expands Market Presence with New Securities Quotation

Nova Eye Medical Limited has announced the application for quotation of 21,000 ordinary fully paid securities on the Australian Securities Exchange, issued under an employee incentive scheme. This move reflects the company’s ongoing efforts to enhance its market presence and incentivize its workforce, potentially impacting its operational dynamics and stakeholder engagement.

Nova Eye Medical Announces Investor Webinar Amid Market Growth

Nova Eye Medical Limited has announced an investor webinar, highlighting its commitment to delivering on promises by selling highly effective ophthalmic products that are in demand among eye surgeons. This announcement underscores the company’s strategic focus on capitalizing on a growing market, which could enhance its industry positioning and potentially benefit stakeholders.

Nova Eye Medical Issues Shares to Consultant, Bolstering Market Position

Nova Eye Medical Ltd has issued 45,236 shares to an American consultant as part of a consulting agreement. This move, executed without the need for disclosure under the Corporations Act, signifies the company’s compliance with regulatory requirements and may enhance its operational capabilities and market positioning.

Nova Eye Medical to Quote New Securities on ASX

Nova Eye Medical Limited has announced the quotation of 45,236 ordinary fully paid securities on the ASX, effective May 6, 2025. This move is part of a consulting agreement in America aimed at enhancing clinical marketing, new product development, peer-to-peer education, and clinical investigations, which could strengthen the company’s market position and stakeholder engagement.

Nova Eye Medical Announces Investor Webinar to Discuss Record Sales and Future Growth Opportunities

Nova Eye Medical has announced an upcoming Investor Webinar on 6 May 2025, where Managing Director Tom Spurling will discuss the company’s March 2025 Quarterly Activities and Cashflow Report. The report highlights record US sales, revenue growth, and improved profitability in glaucoma treatments. Additionally, Nova Eye Medical is exploring opportunities to expand its iTrack™ technology into ocular drug delivery markets, indicating potential future growth and innovation in their product offerings.

Nova Eye Medical Reports Record Sales and Identifies New Growth Opportunities

Nova Eye Medical Limited reported strong financial performance for the March 2025 quarter, with a 27% increase in sales compared to the previous corresponding period, excluding China. The company achieved record sales in the USA, contributing to a significant reduction in losses within the glaucoma segment. The company also identified potential growth opportunities in ocular drug delivery using its proprietary iTrack™ technology, further strengthening its market position.